Renaissance Technologies’s Lifecore Biomedical LFCR Stock Holding History

Renaissance Technologies’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-11,000	Closed	-$56.4K	–	3736
2024 Q2	$56.4K	Buy	+11,000	New	+$65.1K	﹤0.01%	3271
2024 Q1	–	Sell	-36,700	Closed	-$227K	–	3913
2023 Q4	$227K	Sell	36,700 -32,600	-47%	-$226K	﹤0.01%	3088
2023 Q3	$523K	Sell	69,300 -39,951	-37%	-$365K	﹤0.01%	2690
2023 Q2	$1.06M	Sell	109,251 -62,200	-36%	-$380K	﹤0.01%	2436
2023 Q1	$647K	Buy	171,451 +56,300	+49%	+$314K	﹤0.01%	2733
2022 Q4	$746K	Sell	115,151 -3,749	-3%	-$30.9K	﹤0.01%	2706
2022 Q3	$1.06M	Sell	118,900 -7,900	-6%	-$80.3K	﹤0.01%	2465
2022 Q2	$1.26M	Buy	126,800 +8,900	+8%	+$88.1K	﹤0.01%	2545
2022 Q1	$1.36M	Buy	117,900 +1,200	+1%	+$13.4K	﹤0.01%	2515
2021 Q4	$1.29M	Sell	116,700 -4,200	-3%	-$40.8K	﹤0.01%	2461
2021 Q3	$1.11M	Sell	120,900 -79,751	-40%	-$868K	﹤0.01%	2487
2021 Q2	$2.26M	Sell	200,651 -98,000	-33%	-$1.13M	﹤0.01%	2181
2021 Q1	$3.17M	Buy	298,651 +94,652	+46%	+$1.06M	﹤0.01%	1931
2020 Q4	$2.21M	Buy	203,999 +92,699	+83%	+$958K	﹤0.01%	2066
2020 Q3	$1.08M	Buy	111,300 +10,200	+10%	+$97.1K	﹤0.01%	2474
2020 Q2	$805K	Buy	101,100 +82,800	+452%	+$854K	﹤0.01%	2655
2020 Q1	$159K	Buy	+18,300	New	+$190K	﹤0.01%	3141
2019 Q4	–	Sell	-41,937	Closed	-$456K	–	3637
2019 Q3	$456K	Sell	41,937 -64,800	-61%	-$705K	﹤0.01%	2896
2019 Q2	$1M	Sell	106,737 -38,900	-27%	-$393K	﹤0.01%	2678
2019 Q1	$1.79M	Buy	145,637 +10,400	+8%	+$127K	﹤0.01%	2362
2018 Q4	$1.6M	Buy	135,237 +28,686	+27%	+$394K	﹤0.01%	2348
2018 Q3	$1.53M	Buy	106,551 +86,751	+438%	+$1.2M	﹤0.01%	2412
2018 Q2	$295K	Buy	+19,800	New	+$275K	﹤0.01%	2970
2018 Q1	–	Sell	-15,000	Closed	-$189K	–	3477
2017 Q4	$189K	Sell	15,000 -15,000	-50%	-$190K	﹤0.01%	3146
2017 Q3	$389K	Buy	+30,000	New	+$395K	﹤0.01%	2847
2017 Q1	–	Sell	-28,082	Closed	-$388K	–	3318
2016 Q4	$388K	Buy	+28,082	New	+$389K	﹤0.01%	2842
2016 Q2	–	Sell	-20,600	Closed	-$216K	–	3429
2016 Q1	$216K	Sell	20,600 -18,600	-47%	-$204K	﹤0.01%	3059
2015 Q4	$464K	Buy	39,200 +21,200	+118%	+$260K	﹤0.01%	2756
2015 Q3	$210K	Buy	+18,000	New	+$238K	﹤0.01%	2889
2015 Q2	–	Sell	-14,100	Closed	-$197K	–	3296
2015 Q1	$197K	Sell	14,100 -4,300	-23%	-$59.4K	﹤0.01%	2887
2014 Q4	$254K	Sell	18,400 -4,700	-20%	-$60.7K	﹤0.01%	2631
2014 Q3	$283K	Sell	23,100 -13,000	-36%	-$162K	﹤0.01%	2490
2014 Q2	$451K	Sell	36,100 -140,696	-80%	-$1.66M	﹤0.01%	2363
2014 Q1	$1.97M	Sell	176,796 -68,404	-28%	-$750K	﹤0.01%	1777
2013 Q4	$2.97M	Sell	245,200 -113,551	-32%	-$1.36M	0.01%	1517
2013 Q3	$4.38M	Buy	358,751 +135,151	+60%	+$1.89M	0.01%	1236
2013 Q2	$2.95M	Buy	+223,600	New	+$3.09M	0.01%	1376

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies's LFCR Position: Q3 2024 in Review

Renaissance Technologies sold out of Lifecore Biomedical (LFCR) in Q3 2024, closing a stake of 11,000 shares — an estimated $56.4K sold.

Renaissance Technologies first reported a position in LFCR in Q2 2013 and held it in 37 quarters. The position peaked at $4.38M in Q3 2013. 82 funds tracked by Wall St. Rank hold LFCR as of Q3 2024.

Renaissance Technologies reported no remaining Lifecore Biomedical position as of Q3 2024 after selling out during the quarter.
Renaissance Technologies sold 11,000 Lifecore Biomedical shares in Q3 2024, an estimated $56.4K.
Renaissance Technologies first reported a position in Lifecore Biomedical in Q2 2013 and held it in 37 quarters.
Renaissance Technologies's Lifecore Biomedical position peaked at $4.38M in Q3 2013.
82 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2024.

Based on Renaissance Technologies's 13F filing for Q3 2024, filed 13 Nov 2024.